Attached files
file | filename |
---|---|
8-K - 120404_ASNB_FORM 8K_MFA APPOINTMENT - EKIMAS Corp | asnb8k_120404.htm |
EXHIBIT 16.1
April 4, 2012
Securities and Exchange Commission
Washington, D.C. 20549
Commissioners:
We have read AdvanSource Biomaterials Corporation's statements included under Item 4.01 of its
Form 8-K filed on April 4, 2012, and we agree with such statements concerning our firm.
/s/ McGladrey & Pullen, LLP